OTCPK:KALO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Kallo Inc., together with its subsidiary, develops and commercializes customized healthcare solutions. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Kallo's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KALO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.4%

KALO

1.5%

US Healthcare Services

-1.9%

US Market


1 Year Return

3.2%

KALO

57.8%

US Healthcare Services

13.1%

US Market

Return vs Industry: KALO underperformed the US Healthcare Services industry which returned 57.8% over the past year.

Return vs Market: KALO underperformed the US Market which returned 13.1% over the past year.


Shareholder returns

KALOIndustryMarket
7 Day-2.4%1.5%-1.9%
30 Day45.5%0.9%-2.9%
90 Day77.8%12.6%8.2%
1 Year3.2%3.2%58.2%57.8%15.7%13.1%
3 Year-73.3%-73.3%101.1%99.8%38.4%29.1%
5 Year-97.6%-97.6%163.7%161.3%89.3%68.0%

Price Volatility Vs. Market

How volatile is Kallo's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kallo undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Kallo is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Kallo has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Kallo's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Kallo regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Kallo forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

38.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kallo has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Kallo's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Kallo's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Kallo performed over the past 5 years?

22.9%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Kallo has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • Examine Kallo's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Kallo's filings and announcements here.
  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is Kallo's financial position?


Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if KALO's short term assets cover its short term liabilities.

Long Term Liabilities: KALO has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: KALO is debt free.

Reducing Debt: KALO currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: KALO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: KALO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Kallo current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KALO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KALO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KALO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KALO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KALO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.8yrs

Average management tenure


CEO

John Cecil (57 yo)

9.92yrs

Tenure

US$4,850,681

Compensation

Mr. John Cecil founded Kallo Inc. and has been its President since February 29, 2016. Mr. Cecil has been the Chief Executive Officer of Kallo Inc. (Former Name: Diamond Technologies Inc.) since October 20, ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD601.34K).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
John Cecil
Founder9.92yrsUS$4.85m44.11%
$ 8.1m
Lloyd Chiotti
COO, Executive VP & Director9yrsUS$977.00kno data
Samuel Baker
Secretary & Director10.75yrsUS$295.34kno data
Rod MacMillan
Director of Technologyno datano datano data
Marion Lyver
Chief Medical Officerno datano datano data

9.8yrs

Average Tenure

72yo

Average Age

Experienced Management: KALO's management team is seasoned and experienced (9.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Cecil
Founder9.92yrsUS$4.85m44.11%
$ 8.1m
Lloyd Chiotti
COO, Executive VP & Director9yrsUS$977.00kno data
Samuel Baker
Secretary & Director10.75yrsUS$295.34kno data

9.9yrs

Average Tenure

72yo

Average Age

Experienced Board: KALO's board of directors are considered experienced (9.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Kallo Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kallo Inc.
  • Ticker: KALO
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$18.423m
  • Shares outstanding: 1.15b
  • Website: https://www.kalloinc.ca

Number of Employees


Location

  • Kallo Inc.
  • 225 Duncan Mills Road
  • Suite 504
  • Toronto
  • Ontario
  • M3B 3H9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KALOOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 2007

Biography

Kallo Inc., together with its subsidiary, develops and commercializes customized healthcare solutions. It engages in the development of Electronic Medical Record (EMR) Integration Engine, a software that c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 05:56
End of Day Share Price2020/09/22 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.